Saturday 17 October 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.93
0.23
−3.21%
Follow RGNX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 11.12 | 0.00 | 0.00 | 13.15 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 5 | 4 | 2 | 7 | 4 | 1 | 7 | 5 | 2 |
Altman Z-Score |
(2.57) | (2.71) | (0.88) | 0.62 | 3.49 | 2.92 | 18.24 | 25.48 | 36.49 | 25.16 |
P/S ratio |
4.36 | 4.59 | 8.89 | 8.52 | 2.95 | 10.94 | 42.66 | 6.42 | 99.90 | 106.46 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 10.30 | 0.00 | 0.00 | 15.35 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.82) | (6.10) | (3.56) | 0.11 | 5.08 | 2.90 | 10.83 | 19.68 | 11.70 | 13.92 |
Beneish M-Score |
(2.77) | (3.25) | (3.38) | (1.58) | (1.08) | (0.73) | 19.91 | 16.65 | (2.82) | (4.34) |
P/Operating CF |
(14.20) | (12.10) | (19.68) | (24.39) | 4.06 | 42.85 | (58.93) | (338.71) | (75.09) | (23.92) |
P/B ratio |
7.23 | 1.47 | 2.57 | 1.86 | 1.82 | 4.48 | 3.34 | 2.76 | 5.67 | 3.02 |
Price to Tangible BV |
7.23 | 1.47 | 2.57 | 1.86 | 1.82 | 4.48 | 3.34 | 2.76 | 5.67 | 3.02 |
EV/Sales |
3.04 | 1.85 | 5.90 | 5.33 | 1.99 | 7.90 | 34.42 | 4.98 | 84.43 | 86.95 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 5.34 | 0.00 | 0.00 | 11.72 | 0.00 | 0.00 |
EV/Operating CF |
(4.18) | (0.89) | (2.44) | (2.90) | 4.28 | (22.59) | (11.26) | 10.40 | (15.13) | (8.22) |
EV/FCF |
(4.10) | (0.88) | (2.33) | (2.52) | 6.95 | (15.09) | (10.16) | 11.91 | (13.47) | (7.04) |
Quick Ratio |
2.17 | 2.47 | 2.30 | 3.01 | 3.75 | 6.37 | 9.93 | 14.81 | 11.17 | 9.37 |
Current Ratio |
2.38 | 2.69 | 2.57 | 3.19 | 3.98 | 6.52 | 10.25 | 15.24 | 11.64 | 9.66 |
Net Debt/EBITDA |
1.58 | 1.08 | 1.10 | 1.49 | (2.61) | 4.34 | 2.07 | (3.38) | 2.25 | 1.43 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.08% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Asset Turnover |
0.37 | 0.16 | 0.13 | 0.12 | 0.52 | 0.26 | 0.07 | 0.59 | 0.06 | 0.02 |
Operating CF/Net income |
0.64 | 0.76 | 0.83 | 0.74 | 1.71 | 0.49 | 1.14 | 1.05 | 0.79 | 0.77 |
Capex/Depreciation |
(0.15) | (0.15) | (0.55) | (1.74) | (5.46) | (2.83) | (1.97) | (2.80) | (1.59) | (3.20) |
Interest Coverage |
(3.58) | (18.43) | (39.07) | (11.30) | 6.09 | (154.65) | (10.85) | 5.47 | (27.94) | (33.72) |
| (107.00%) | (79.49%) | (63.65%) | (43.78%) | 22.39% | (26.87%) | (19.76%) | 28.89% | (42.45%) | (33.27%) | |
| (42.19%) | (43.68%) | (37.45%) | (28.79%) | 14.03% | (18.45%) | (18.19%) | 26.92% | (39.40%) | (31.95%) | |
ROIC |
0.00% | (584.21%) | (459.32%) | (108.41%) | 32.58% | 0.00% | (60.48%) | 28.25% | (213.15%) | (56.57%) |
Return on Tangible Assets |
(72.33%) | (77.67%) | (78.23%) | (65.61%) | 24.59% | (21.98%) | (27.84%) | 29.01% | (43.67%) | (67.69%) |
Average Days of Receivables |
56.49 | 89.68 | 100.27 | 90.93 | 25.17 | 101.54 | 395.20 | 14.34 | 16.61 | 82.08 |
Research and Development Expense of Revenue |
133.95% | 250.24% | 257.38% | 215.09% | 38.58% | 107.59% | 352.47% | 38.38% | 550.60% | 991.11% |
Selling, General and Administrative Expense of Revenue |
48.62% | 91.95% | 98.06% | 75.65% | 16.87% | 41.29% | 147.06% | 16.86% | 261.99% | 514.06% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
20.28% | 46.16% | 44.62% | 36.18% | 8.25% | 20.67% | 76.22% | 7.62% | 102.04% | 153.21% |
Graham Net Nets |
(0.09) | 0.19 | 0.09 | 0.10 | 0.12 | 0.12 | 0.20 | 0.22 | 0.15 | 0.17 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 34.52 | 0.00 | 0.00 | 33.05 | 0.00 | 0.00 |
Earnings Yield |
(26.11%) | (59.64%) | (32.88%) | (29.21%) | 8.99% | (6.59%) | (6.32%) | 7.60% | (7.11%) | (12.92%) |
Free Cash Flow Yield |
(17.02%) | (45.87%) | (28.47%) | (24.81%) | 9.71% | (4.79%) | (7.94%) | 6.52% | (6.28%) | (11.61%) |
Revenue per Share |
3.30 | 1.68 | 2.06 | 2.61 | 11.08 | 4.15 | 0.96 | 6.54 | 0.35 | 0.17 |
Operating CF per Share |
(2.40) | (3.50) | (4.99) | (4.81) | 5.16 | (1.45) | (2.94) | 3.13 | (1.94) | (1.84) |
Capex per Share |
(0.05) | (0.05) | (0.23) | (0.71) | (1.98) | (0.72) | (0.32) | (0.40) | (0.24) | (0.31) |
Free Cash Flow per Share |
(2.45) | (3.55) | (5.22) | (5.52) | 3.17 | (2.17) | (3.25) | 2.73 | (2.18) | (2.15) |
Cash per Share |
4.46 | 4.74 | 6.29 | 8.45 | 10.78 | 12.76 | 8.07 | 9.57 | 5.38 | 3.39 |
Shareholders Equity per Share |
1.99 | 5.24 | 7.13 | 11.96 | 18.01 | 10.13 | 12.27 | 15.22 | 6.13 | 6.12 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.99 | 5.24 | 7.13 | 11.96 | 18.01 | 10.13 | 12.27 | 15.22 | 6.13 | 6.12 |
Free Cash Flow |
(126.38) | (175.56) | (228.37) | (238.21) | 134.70 | (80.93) | (119.42) | 91.37 | (65.15) | (56.71) |
Working Capital |
163.19 | 174.81 | 204.70 | 285.54 | 388.35 | 449.75 | 311.36 | 315.74 | 153.56 | 83.70 |
Capital Expenditures |
(2.41) | (2.44) | (9.96) | (30.72) | (84.17) | (26.87) | (11.72) | (13.28) | (7.16) | (8.15) |
Net Current Asset Value |
(69.02) | 71.66 | 72.74 | 98.90 | 169.22 | 200.79 | 297.32 | 302.95 | 152.35 | 82.38 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 5.85 | 0.00 | 0.00 | 12.35 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.03 | 0.11 | 0.27 | 0.18 | 0.17 | 0.33 | 0.06 | 0.69 | 1.78 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 8.67 | 0.00 | 0.00 | 15.92 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.15 | 0.14 | 0.14 | 0.12 | 0.12 | 0.17 | 0.21 | 0.17 | 0.32 | 0.27 |
Cash ROIC |
(37.97%) | (35.51%) | (38.90%) | (27.04%) | 11.03% | (9.48%) | (16.00%) | 10.95% | (18.95%) | (22.57%) |
Accounts Receivable Turnover |
7.28 | 3.68 | 3.41 | 3.73 | 12.47 | 3.81 | 1.51 | 48.24 | 13.81 | 2.90 |
Accounts Payable Turnover |
0.92 | 1.47 | 1.49 | 2.83 | 4.71 | 4.19 | 1.52 | 2.09 | 0.54 | 0.75 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
384.06 | 247.90 | 223.49 | 182.10 | 80.19 | 108.56 | 283.86 | 167.05 | 1,032.00 | 587.27 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
23.43 | 22.63 | 26.44 | 30.26 | 37.72 | 40.57 | 23.37 | 4.53 | 0.75 | 1.58 |
Average Payables |
22.08 | 22.79 | 25.00 | 19.30 | 11.00 | 8.52 | 5.41 | 4.62 | 3.19 | 1.28 |
Average Assets |
459.51 | 519.98 | 703.62 | 973.59 | 911.03 | 603.04 | 520.86 | 371.25 | 185.70 | 197.06 |
Average Common Equity |
181.19 | 285.70 | 413.97 | 640.25 | 571.03 | 413.98 | 479.52 | 345.94 | 172.38 | 189.27 |
Columns are period end dates